Validation of Blood Collection Procedures for the Determination of Circulating Vascular Endothelial Growth Factor (VEGF) in Different Blood Compartments
Free accessResearch articleFirst published online 2001
Validation of Blood Collection Procedures for the Determination of Circulating Vascular Endothelial Growth Factor (VEGF) in Different Blood Compartments
Studies on circulating VEGF have reported mixed results, possibly due to a lack of standardization of the pre-analytical phase. The aim of our investigation was to standardize the sampling procedure for the determination of VEGF in different blood fractions.
Basic procedures.
We evaluated various clotting times for obtaining serum in 30 subjects, as well as different procedures for the preparation of plasma Edinburgh anticoagulant mixture (EDTA, PGE1, theophylline) and CTAD. VEGF was also assayed in lysed whole blood. In vitro platelet activation was monitored by measuring the levels of PF4. VEGF and PF4 were measured using commercially available enzyme-linked immunoassays.
Main findings.
Clotting time increased the release of VEGF, which reached a plateau between 2 and 4 hours. The percent increase of VEGF at 2 hours ranged from 118% to 4515% (median 327%) compared to samples centrifuged within 10 min from withdrawal. VEGF was not different and PF4 was very low or undetectable in Edinburgh plasma and CTAD plasma, while it was significantly higher in sodium citrate plasma. VEGF in CTAD plasma was not correlated with platelet count or leukocytes. Serum VEGF did not correlate with the leukocyte number, but it correlated significantly with the platelet count.
Principal conclusions.
The procedures for sample collection described above are highly standardized and easy to perform in a routine setting. We therefore suggest systematic evaluation of VEGF in CTAD plasma, in serum (clotting for 2 hours at room temperature) and in whole blood, until prospective controlled clinical studies will have clarified in which blood compartment(s) VEGF provides clinically relevant information.
ToiM., KondoS., SuzukiH.Quantitative analysis of vascular endothelial growth factor in primary breast cancer.Cancer1996; 77: 1101–6.
4.
GaspariniG.Prognostic value of vascular endothelial growth factor (VEGF) in breast cancer.The Oncologist2000; 5: 37–44.
5.
HanataniM., TanakaY., KondoS., OhmoriI., SuzukiH.Sensitive chemiluminescence enzyme immunoassay for vascular endothelial growth factor/vascular permeability factor in human serum.Biosci Biotechnol Biochem1995; 59: 1958–9.
6.
YamamotoY., ToiM., KondoS.Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients.Clin Cancer Res1996; 2: 821–6.
7.
DirixL.Y., VermeulenP.B., PawinskiA.Elevated levels of the angiogenic cytokines basic fibroplast growth factor and vascular endothelial growth factor in sera of cancer patients.Br J Cancer1997; 76: 238–43.
8.
SalvenP., MäenpääH., OrpanaA., AlitaloK., JoensuuH.Serum vascular endothelial growth factor is often elevated in disseminated cancer.Clin Cancer Res1997; 3: 647–51.
9.
SekoY., ImaiY., SuzukiS.Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy.Clin Sci1997; 92: 453–4.
10.
AkiyoshiF., SataM., SuzukiH.Serum vascular endothelial growth factor levels in various liver diseases.Dig Dis Sci1998; 43: 41–5.
11.
BenoyI., VermeulenP., WuytsH., DirixL.Vascular endothelial cell growth factor (VEGF) serum concentrations change according to the phase of the menstrual cycle.Eur J Cancer1998; 34: 1298–9.
12.
FujisakiK., MitsuyamaK., ToyonagaA., MatsuoK., TanikawaK.Circulating vascular endothelial growth factor in patients with colorectal cancer.Am J Gastroenterol1998; 93: 249–52.
13.
HeerK., KumarH., SpeirsV.Vascular endothelial growth factor in premenopausal women – indicator of the best time for breast cancer surgery?Br J Cancer1998; 78: 1203–7.
14.
HyodoI., DoiT., EndoH.Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer.Eur J Cancer1998; 34: 2041–5.
15.
KumarH., HeerK., LeeP.W.R.Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer.Clin Cancer Res1998; 4: 1279–85.
16.
ObermairA., TempferC., HeflerL.Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer.Br J Cancer1998; 77: 1870–4.
17.
SalvenP., RuotsalainenT., MattsonK., JoensuuH.High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer.Int J Cancer (Predict Oncol)1998; 79: 144–6.
18.
AgravalR., ConwayG.S., SladkeviciusP.Serum vascular endothelial growth factor (VEGF) in the normal menstrual cycle: association with changes in ovarian and uterine Doppler blood flow.Clin Endocrinol1999; 50: 101–6.
19.
BalsariA., MaierJ.A.M., ColnaghiM.I., MénardS.Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma.Lab Invest1999; 79: 897–902.
20.
EdgrenM., LennernäsB., LarssonA., NilssonS.Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas.Anticancer Res1999; 19: 869–74.
21.
GadducciA., FerdeghiniM., FanucchiA.Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome.Anticancer Res1999; 19: 1401–6.
22.
GraevenU., AndreN., AchillesE., ZornigC., SchmiegelW.Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma.J Cancer Res Clin Oncol1999; 125: 577–81.
23.
HeflerL., TempferC., ObermairA.Serum concentrations of vascular endothelial growth factor in vulvar cancer.Clin Cancer Res1999; 5: 2806–9.
24.
KraftA., WeindelK., OchsA.Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.Cancer1999; 5: 178–87.
25.
OehlerM.K., CaffierH.Diagnostic value of serum VEGF in women with ovarian tumors.Anticancer Res1999; 19: 2519–22.
26.
SalgadoR., VermeulenP.B., BenoyI.Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.Br J Cancer1999; 80: 892–7.
27.
SalvenP., PerhoniemiV., TykkäH., MäenpääH., JoensuuH.Serum VEGF levels in women with a benign breast tumor or breast cancer.Breast Cancer Res Treat1999; 53: 161–6.
28.
SatoK., TsuchiyaN., SasakiR.Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma.Jpn J Cancer Res1999; 90: 874–9.
29.
AdamsJ., CarderP.J., DowneyS.Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum and tissue VEGF and microvessel density and effects of tamoxifen.Cancer Res2000; 60: 2898–905.
30.
VerheulH.M.W., HoekmanK., Luykx-de BakkerS.Platelet: transporter of vascular endothelial growth factor.Clin Cancer Res1997; 3: 2187–90.
31.
BanksR.E., ForbesM.A., KinseyS.E.Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology.Br J Cancer1998; 77: 956–64.
32.
MaloneyJ.P., SillimanC.C., AmbrusoD.R., WangJ., TuderR.M., VoelkelN.F.In vitro release of vascular endothelial growth factor during platelet aggregation.Am J Physiol1998; 275: H1054–61.
33.
WebbN.J.A., BottomleyM.J., WatsonC.J., BrenchleyP.E.C.Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease.Clin Sci1998; 94: 395–404.
34.
SalvenP., OrpanaA., JoensuuH.Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor.Clin Cancer Res1999; 5: 487–91.
35.
WynendaeleW., DeruaR., HoylaertsM.F.Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to studying an angiogenic marker in vivo.Ann Oncol1999; 10: 965–71.
36.
GunsiliusE., PetzerA., StockhammerG.Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood.Oncol2000; 58: 169–74.
37.
MalonneH., LangerI., KissR., AtassiG.Mechanism of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.Clin Exp Metastasis1999; 17: 1–14.
38.
GaspariniG., GionM.Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints.Cancer J2000; 6: 117–31.
39.
BoughtonB.J., AllingtonM.J., KingA.Platelet and plasma β-thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis.Br J Haematol1978; 40: 125–32.
40.
CortellazzoS., VieroP., BarbuiT.Platelet activation in myeloproliferative disorders.Thromb Haemost1981; 45: 211–13.
41.
FilesJ.C., MalpassT.W., YeeE.K., RitchieJ.L., HarkerL.A.Studies of human platelet alpha-granule release in vivo.Blood1981; 58: 607–18.
42.
WhiteG.C., MaroufA.A.Platelet factor 4 in patients with coronary artery disease.J Lab Clin Med1981; 97: 369–78.
43.
FabrisF., LuzzattoG., GirolamiA.The value of βTG/PF4 ratio in patients with high platelet count.Thromb Haemost1985; 53: 288.
44.
LuzzatoG., FabrisF., MazzucatoM., GirolamiA.PF 4 versus βTG as evidence for platelet activation in myeloproliferative disorders.Scand J Haematol1985; 35: 299–304.
45.
KaplanK.L., OwenJ.Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo.Blood1981; 57: 199–202.
